Teva receives CHMP positive opinion for DuoResp® Spiromax® for the treatment of patients diagnosed with Asthma and COPD in Europe
21 February 2014 | By Teva Pharmaceutical Industries Ltd
Innovative new inhaler for asthma and COPD patients
List view / Grid view
News
Novartis shows continued commitment in Japan with Lucentis® approval in fourth Japanese indication, diabetic macular edema
21 February 2014 | By Novartis
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema, a leading cause of vision loss among patients with diabetes...
Ulcerative colitis not well-controlled in patients receiving conventional treatments
21 February 2014 | By Merck
MSD has announced full study findings from a pan-European observational study that showed the majority of moderate-to-severe ulcerative colitis patients who were treated with conventional therapies failed to achieve well-controlled disease status...
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD
21 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse®...
FDA accepts for review Merck’s Biologics License Application for V503, investigational 9-valent human papillomavirus vaccine
20 February 2014 | By Merck
Merck announced that the Biologics License Application for V503...
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
20 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro®...
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
19 February 2014 | By Novartis
Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment...
European Medicines Agency and US Food and Drug Administration strengthen collaboration in pharmacovigilance area
19 February 2014 | By The European Medicines Agency
The European Medicines Agency and the United States Food and Drug AdministrationExternal link icon have set up a new 'cluster' on pharmacovigilance topics...
Antibody Drug Conjugates (ADC)
19 February 2014 | By Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: "Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?"
Is Big Pharma still actively engaging in outsourcing?
19 February 2014 | By Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc
Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”
Photomultiplier based plate-readers vs. CCD imaging based plate-readers
19 February 2014 | By Edward Dell, International Marketing Director, BMG Labtech
Edward Dell, International Marketing Director, BMG Labtech answers the question "Although photomultiplier based plate-readers offer increased sensitivity compared to CCD imaging based plate-readers, they take longer to collect data from a microtitre plate. How do your customers balance throughput versus sensitivity when considering which plate-reader to purchase?"
Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
18 February 2014 | By Avillion LLP
Avillion LLP announced it has appointed Dr Allison Jeynes-Ellis MB, ChB, FFPM as Chief Executive Officer...
Novartis expands cancer immunotherapy research program with acquisition of CoStim
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
European Medicines Agency welcomes new Head of IT Development Department
17 February 2014 | By The European Medicines Agency
The European Medicines Agency is pleased to welcome Dina Tsiambaou as the new Head of IT Development Department in the Information Technology Division...
MSD Animal Health receives marketing authorization from European Commission for BRAVECTO™
17 February 2014 | By Merck
MSD Animal Health announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use, the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO™...
